10-Q: REMSleep Holdings Secures $143,000 Convertible Note Amidst Ongoing Financial Challenges

REMSleep Holdings, a company focused on sleep apnea solutions, has obtained a $143,000 convertible promissory note while reporting a net loss of $252,580 for the quarter ending March 31, 2024.

Summary

• REMSleep Holdings secured a $143,000 convertible promissory note from 1800 Diagonal Lending LLC on January 10, 2024, with a 10% interest rate and a maturity date of January 10, 2025.
• The note includes an original issue discount of $13,000, resulting in a purchase price of $130,000.
• The note is convertible into common stock at a 25% discount to the market price, beginning 180 days after the issue date.
• The company reported a net loss of $252,580 for the three months ended March 31, 2024, compared to a net loss of $226,259 for the same period in 2023.
• Revenue decreased to $57,881 from $85,655 in the prior year's quarter, while cost of goods sold also decreased to $13,590 from $73,576.
• Operating expenses decreased to $168,506 from $233,055, primarily due to reductions in professional fees, compensation, and lease expenses.
• The company's cash balance increased slightly to $730,625 as of March 31, 2024, from $719,100 at the end of 2023.
• The company has a significant accumulated deficit of $14,445,339 as of March 31, 2024.
• There is substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for additional financing.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with increasing losses, decreasing revenue, and a going concern warning. While there are some positive aspects like cost-cutting and securing a convertible note, the overall sentiment is negative due to the company's precarious financial situation and operational challenges.

Positives

• Operating expenses decreased significantly, indicating cost-cutting measures.
• The company secured a $143,000 convertible note, providing additional funding.
• The company's cash balance increased slightly during the quarter.

Negatives

• The company experienced a net loss of $252,580 for the quarter.
• Revenue decreased compared to the same period last year.
• The company has a substantial accumulated deficit of $14,445,339.
• There is substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and the need for additional financing.
• The company's revenue decreased, indicating potential challenges in sales and market penetration.
• The company's accumulated deficit is substantial, posing a risk to long-term financial stability.
• The company is dependent on obtaining additional financing to continue operations.
• The company's internal controls are not effective due to a lack of segregation of duties.

Future Outlook

The company plans to continue financing operations through debt and/or equity financing as needed and expects FDA approval for its DeltaWave product by the third quarter of 2024. The company's future success is dependent on its ability to generate capital financing and increase profitability.

Management Comments

• Management acknowledges substantial doubt about the company's ability to continue as a going concern.
• Management plans to obtain funding from new investors and implement a plan to generate sales.

Industry Context

The company operates in the competitive sleep apnea device market, where mask comfort and compliance are key concerns. The company is developing a new nasal-pillows type interface to address these issues. The company's financial results highlight the challenges faced by smaller companies in this industry, particularly in achieving profitability and securing funding.

Comparison to Industry Standards

• The company's revenue of $57,881 for the quarter is significantly lower than established medical device companies, such as ResMed or Philips, which report revenues in the hundreds of millions or billions per quarter.
• The net loss of $252,580 is typical for early-stage medical device companies that are still in the development and commercialization phase, but it is a concern given the company's accumulated deficit.
• The company's reliance on convertible debt financing is common for smaller companies, but it also indicates a higher risk profile compared to companies with established revenue streams and access to traditional financing.
• The company's focus on a new CPAP interface aligns with the industry trend of improving patient comfort and compliance, but the company faces competition from established players with larger R&D budgets and market presence.

Management Changes

Related Party Transactions

• The company made cash payments to the CEO, Thomas J. Wood, and the brother of the CEO for services.
• The company has accrued compensation due to Mr. Wood and the former Chairman, Russell Bird.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern issues.
• Employees may be affected by potential cost-cutting measures or the company's uncertain future.
• Customers may be impacted by potential delays in product development and availability.
• Creditors face increased risk due to the company's financial difficulties.

Next Steps

• The company plans to continue seeking funding from new investors.
• The company aims to complete testing and submit its 510k application for the DeltaWave product.
• The company intends to implement a plan to generate sales.

Key Dates

Keywords

convertible note, sleep apnea, financial results, net loss, revenue, operating expenses, going concern, debt financing, common stock, derivative liability